Intern – In Vitro Immunology at Abata Therapeutics

Rockville, Maryland, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

The candidate must be currently enrolled in a college program related to Immunology or Cell Biology, completed introductory laboratory coursework in Cell Biology, Molecular Biology, Biochemistry, Immunology, or a related field, and be interested in gaining hands-on experience with mammalian cell culture and sterile technique. They should also be self-motivated to find solutions and drive to results, and willing to use the same energy to ensure the success of everyone in the team, with strong interpersonal skills to foster an open and collaborative environment and excellent record-keeping abilities to document analytical data generated.

Responsibilities

The intern will routinely perform mammalian cell culture to maintain tumor cell lines, execute in vitro immune assays with tumor and immune cells to evaluate biologic candidates, measure cytokine and analyte expression using ELISA, or MSD assays, analyze data using Prism, Excel, etc., and present results in team meetings. They will also record experimental results in an electronic notebook.

Skills

Mammalian Cell Culture

Sterile Technique

ELISA

MSD Assays

GraphPad Prism

Microsoft Excel

In Vitro Immune Assays

Cytokine Analysis

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free